Discuss FOXO4-DRI on glp1chat
Join the forum to discuss research with other members.
At a glance
FOXO4-DRI is designed to disturb a survival link used by some aging cells. In experimental models, breaking the FOXO4–p53 interaction can make those cells easier to remove, which is why researchers study its effects on tissues.
Some older, damaged cells stop dividing but remain in tissue and release signals that can disturb nearby cells. FOXO4 helps certain such cells avoid a normal self-destruction pathway. FOXO4-DRI was designed to loosen that protection, allowing p53-related cell death in experimental models. The original work studied cells and mice; removing a marker of aging is not the same as showing a safe human anti-aging benefit.
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited work concerns senescent-cell burden and tissue responses. These findings do not establish a clinical anti-aging regimen.[2][3][4]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of FOXO4-DRI.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 10 mg · 1 source tables
Standard / Gradual Approach (3 mL = ~3.33 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–4 | 250 mcg | 7.5 units (0.075 mL) |
| Weeks 5–8 | 375 mcg | 11 units (0.11 mL) |
| Weeks 9–12 | 500 mcg | 15 units (0.15 mL) |
| Weeks 13–16 | 500 mcg | 15 units (0.15 mL) |
Frequency: Inject once daily subcutaneously[6]. This schedule uses the standard 3.0 mL dilution to maintain injection volumes under 0.2 mL for all doses. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once-daily regimen.
- Goal: Selectively clear senescent cells via disruption of FOXO4–p53 binding[1][2].
- Schedule: Daily subcutaneous injections for 8–16 weeks with gradual dose escalation.
- Dose Range: 250–500 mcg daily; starting low and titrating upward over time.
- Reconstitution: 3.0 mL per 10 mg vial (~3.33 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen at −20 °C (−4 °F); reconstituted refrigerated at 2–8 °C (35.6–46.4 °F); avoid repeated freeze–thaw[7].
Suggested daily titration approach.
- Start: 250 mcg daily for the first 4 weeks; increase gradually as tolerated.
- Mid-Phase: 375 mcg daily during Weeks 5–8.
- Target: 500 mcg daily by Weeks 9–16.
- Frequency: Once per day (subcutaneous)[6].
- Cycle Length: 8–16 weeks; longer cycles may use intermittent dosing schedules as tolerated[3].
- Timing: Any consistent time; rotate injection sites to minimize local irritation.
Read this protocol on Pep Science → · View cited documents ↓
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake)[7].
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) or below in dry, dark conditions; minimize moisture exposure[7].
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 1 month when using bacteriostatic water[7].
- Allow vials to reach room temperature before opening to reduce condensation uptake.
- If long-term storage of reconstituted solution is needed, aliquot into single-use vials and freeze to minimize degradation[7].
Injection Technique
General subcutaneous guidance from clinical best-practice resources[8][9][10].
- Clean the vial stopper and skin with alcohol; allow to dry[8].
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue (use 90° for adequate fat layer, 45° if thin)[10][11].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[10].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy and local irritation[9].
- Release the pinch and withdraw the needle; apply gentle pressure with gauze if slight bleeding occurs.
Materials & quantity planning
Source materials checklist · 10 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (FOXO4-DRI, 10 mg each):
- 8 weeks ≈ 3 vials
- 12 weeks ≈ 4 vials
- 16 weeks ≈ 5 vials
-
Insulin Syringes (U-100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 12 mL → 2 × 10 mL bottles
- 16 weeks (5 vials): 15 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100-count boxes
- 12 weeks: 168 swabs → recommend 2 × 100-count boxes
- 16 weeks: 224 swabs → recommend 3 × 100-count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 10 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 07
- 08
Public health resource
MedlinePlus — Subcutaneous (SQ) injections: technique, site selection, and safety (opens in a new tab)medlineplus.gov
Back to overview ↑ - 09
Source document
American Diabetes Association — Insulin injection site rotation and lipohypertrophy prevention (opens in a new tab)diabetesjournals.org
Back to overview ↑ - 10
Public health resource
CDC — Vaccine administration: subcutaneous route (angle, site; no aspiration) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 11
- 12
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Research publication
PMC — Subcutaneous Drug Injection Review: pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑